{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:29Z","timestamp":1787026709217,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several BRAF kinase inhibitors (BRAFis), MEK kinase inhibitors (MEKis), and immune checkpoint inhibitors have been linked with the occurrence of Vogt-Koyanagi-Harada (VKH)-like uveitis. However, there are no reported cases of VKH-like uveitis induced by the combined administration of dabrafenib, trametinib, and cadonilimab to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This paper presents a case of VKH-like uveitis in a patient with inguinal melanoma following combined treatment with dabrafenib, trametinib, and cadonilimab. Four months after the initiation of this combined therapy, the patient developed severe bilateral acute panuveitis complicated by exudative retinal detachment, and a diagnosis of bilateral VKH-like uveitis was considered. The patient\u2019s ocular condition of both eyes improved after the discontinuation of dabrafenib and trametinib, along with the administration of topical and systemic glucocorticoid therapy. At the time of drug discontinuation, the patient\u2019s metastatic liver lesions remained stable, and no melanoma progression was observed during the 1-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report demonstrates that VKH-like uveitis may occur in patients receiving combined treatment with dabrafenib, trametinib, and cadonilimab, and emphasizes the importance of monitoring for ocular complications in patients undergoing long-term treatment with this regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1804008","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:52:13Z","timestamp":1782280333000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Vogt-Koyanagi-Harada-like uveitis associated with combined dabrafenib\/trametinib and cadonilimab therapy for cutaneous melanoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Han","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi","place":["Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi","place":["Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi","place":["Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi","place":["Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi","place":["Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi","place":["Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi","place":["Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3760\/cma.j.cn112142-20230313-00098","article-title":"[Chinese expert consensus on the clinical diagnosis and treatment of Vogt-Koyanagi-Harada syndrome (2023)].","volume":"59","year":"2023","journal-title":"Zhonghua Yan Ke Za Zhi."},{"key":"B2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/bjophthalmol-2020-316256","article-title":"Epidemiology of 2000 Chinese uveitis patients from northeast China.","volume":"105","author":"Hao","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.preteyeres.2016.02.002","article-title":"Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment.","volume":"52","author":"Du","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with Dabrafenib plus trametinib in metastatic melanoma.","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/08820538.2025.2468381","article-title":"Incidence and management of retinopathy and uveitis in patients receiving BRAF\/MEK inhibitor therapy.","volume":"40","author":"Nakajima","year":"2025","journal-title":"Semin Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/08820538.2024.2433636","article-title":"Ocular immune-related adverse events associated with PD-1 inhibitors: from molecular mechanisms to clinical management.","volume":"40","author":"Gong","year":"2025","journal-title":"Semin Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1080\/09273948.2024.2401626","article-title":"Case report and literature review of Vogt-Koyanagi-Harada-like uveitis secondary to Dabrafenib and Trametinib: 4-year follow-up using retinal multimodal imaging.","volume":"32","author":"Ucan Gunduz","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","article-title":"ERK\/MAPK signalling pathway and tumorigenesis.","volume":"19","author":"Guo","year":"2020","journal-title":"Exp Ther Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"428e","DOI":"10.1016\/j.ccell.2025.02.001","article-title":"FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.","volume":"43","author":"Lubrano","year":"2025","journal-title":"Cancer Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant Dabrafenib plus trametinib in stage iii melanoma.","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1111\/1346-8138.17594","article-title":"A case of malignant melanoma in which adalimumab was effective for steroid-resistant uveitis caused by Dabrafenib\/Trametinib combination therapy.","volume":"52","author":"Nakano","year":"2025","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/1346-8138.17082","article-title":"Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF\/MEK inhibitors in melanoma patients with HLA-DRB1*04.","volume":"51","author":"Amagai","year":"2024","journal-title":"J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/iju5.12801","article-title":"Vogt-Koyanagi-Harada disease-like uveitis induced by nivolumab in metastatic renal cell carcinoma.","volume":"8","author":"Imai","year":"2024","journal-title":"IJU Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"rjae104","DOI":"10.1093\/jscr\/rjae104","article-title":"VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report.","volume":"2024","author":"Gunaratnam","year":"2024","journal-title":"J Surg Case Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting iymphocyte function.","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1751-1097.2008.00316.x","article-title":"Role of ocular melanin in ophthalmic physiology and pathology.","volume":"84","author":"Hu","year":"2008","journal-title":"Photochem Photobiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2024.12.028","article-title":"Pathogenic mechanisms of immune checkpoint inhibitor (ici)-associated retinal and choroidal adverse reactions.","volume":"272","author":"Haliyur","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1167\/iovs.08-2536","article-title":"Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism.","volume":"50","author":"Sugita","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exer.2007.09.007","article-title":"Functional expression of B7H1 on retinal pigment epithelial cells.","volume":"86","author":"Usui","year":"2008","journal-title":"Exp Eye Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13580","DOI":"10.1038\/s41598-023-40565-z","article-title":"HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.","volume":"13","author":"Takeuchi","year":"2023","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","article-title":"Ocular safety profile of braf and mek inhibitors: data from the world health organization pharmacovigilance database.","volume":"128","author":"Mettler","year":"2021","journal-title":"Ophthalmology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","article-title":"Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes.","volume":"29","author":"Dow","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/CMR.0000000000000933","article-title":"Uveitis associated with immune checkpoint inhibitors or BRAF\/MEK inhibitors in patients with malignant melanoma.","volume":"33","author":"Sada","year":"2023","journal-title":"Melanoma Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/ICB.0000000000001251","article-title":"Vogt-Koyanagi-Harada disease-like uveitis in a patient with advanced melanoma treated by sequential administration of nivolumab and Dabrafenib\/Trametinib therapy.","volume":"17","author":"Madoe","year":"2023","journal-title":"Retin Cases Brief Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/09273948.2021.2025250","article-title":"Multimodal imaging approach in a patient with vogt-Koyanagi-Harada-like syndrome due to Dabrafenib and Trametinib use for cutaneous melanoma.","volume":"31","author":"Bellanca","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"B28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3928\/23258160-20230524-01","article-title":"Vogt-Kayanagi-Harada-like uveitis induced by Dabrafenib\/Trametinib therapy for cutaneous malignant melanoma.","volume":"54","author":"Kaymak","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"B29","doi-asserted-by":"publisher","first-page":"N109","DOI":"10.1177\/1120672120962044","article-title":"Case of Vogt-Koyanagi-Harada-like uveitis secondary to Dabrafenib\/Trametinib therapy for advanced melanoma.","volume":"32","author":"Brambati","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/09273948.2019.1695860","article-title":"Intravitreal steroid treatment for uveitis associated with Dabrafenib and Trametinib for metastatic cutaneous melanoma.","volume":"29","author":"Woltsche","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.oftal.2018.01.008","article-title":"Uveitis and serous retinal detachment secondary to systemic Dabrafenib and Trametinib.","volume":"93","author":"Rueda-Rueda","year":"2018","journal-title":"Arch Soc Esp Oftalmol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1346-8138.14273","article-title":"HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and Dabrafenib\/Trametinib therapy.","volume":"45","author":"Fujimura","year":"2018","journal-title":"J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12348-015-0049-9","article-title":"Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.","volume":"5","author":"Draganova","year":"2015","journal-title":"J Ophthalmic Inflamm Infect"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1804008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:52:18Z","timestamp":1782280338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1804008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1804008"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1804008","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1804008"}}